Firm News
Partner Katie Rubino Quoted in Life Sciences Intellectual Property Review’s Article “Trump’s march-in rights threat: Why pharma is rethinking collaborations.”
On September 9, 2025, Partner Katie Rubino Quoted in Life Sciences Intellectual Property Review’s Article “Trump’s march-in rights threat: Why pharma is rethinking collaborations.”
This article discusses growing concerns around government intervention in university-held intellectual property, which could disrupt early-stage drug development and deter investment in spin-outs. In response, pharmaceutical companies are being urged to diversify their IP strategies and seek industry collaborations to reduce reliance on academic institutions.
Rubino highlights the importance of strategic importance of intellectual property, stating that “pharma companies should think about IP diversification.” She advises firms to assess gaps in their portfolios, reinforce their own IP holdings, and explore collaborations with other pharmaceutical companies rather than relying solely on universities.
To see Katie’s comments and read the article in its entirety, click here. You must be subscribed to view the entire article.
